Harrow, Inc. (HROW) stock
HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.12+1.82 (+6.43%)
Close on Nov 13, 2026Market cap $1.13BP/E –Yield –
Harrow EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Harrow's EPS for the twelve months ending Sep 30, 2026 was -$0.77. For fiscal 2025 it was -$0.14. The highest annual figure on record is $0.61 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.14 | – |
| FY2024 | Dec 31, 2024 | -$0.49 | – |
| FY2023 | Dec 31, 2023 | -$0.75 | – |
| FY2022 | Dec 31, 2022 | -$0.51 | – |
| FY2021 | Dec 31, 2021 | -$0.69 | – |
| FY2020 | Dec 31, 2020 | -$0.13 | -1400.0% |
| FY2019 | Dec 31, 2019 | $0.01 | -98.4% |
| FY2018 | Dec 31, 2018 | $0.61 | – |
| FY2017 | Dec 31, 2017 | -$0.60 | – |
| FY2016 | Dec 31, 2016 | -$1.50 | – |
| FY2015 | Dec 31, 2015 | -$1.66 | – |
| FY2014 | Dec 31, 2014 | -$1.11 | – |
| FY2013 | Dec 31, 2013 | -$0.88 | – |
| FY2012 | Dec 31, 2012 | -$1.24 | – |
| FY2011 | Dec 31, 2011 | -$2.65 | – |
| FY2010 | Dec 31, 2010 | -$0.80 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.25 | +733.3% |
| Q2 FY2026 | Jun 30, 2026 | -$0.46 | -453.8% |
| Q1 FY2026 | Mar 31, 2026 | -$0.74 | – |
| Q4 FY2025 | Dec 31, 2025 | $0.18 | -5.3% |
| Q3 FY2025 | Sep 30, 2025 | $0.03 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.13 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.50 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.19 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.12 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.18 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.38 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.26 | -750.0% |
| Q3 FY2023 | Sep 30, 2023 | -$0.13 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.14 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.22 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.04 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.24 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.23 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.09 | -1000.0% |
| Q4 FY2021 | Dec 31, 2021 | -$0.27 | -775.0% |
| Q3 FY2021 | Sep 30, 2021 | -$0.31 | -196.9% |
| Q2 FY2021 | Jun 30, 2021 | -$0.11 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.01 | – |
| Q4 FY2020 | Dec 31, 2020 | $0.04 | -55.6% |
| Q3 FY2020 | Sep 30, 2020 | $0.32 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.01 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.50 | -216.3% |
| Q4 FY2019 | Dec 31, 2019 | $0.09 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.45 | -509.1% |
| Q2 FY2019 | Jun 30, 2019 | -$0.09 | – |
| Q1 FY2019 | Mar 31, 2019 | $0.43 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.12 | – |
| Q2 FY2018 | Jun 30, 2018 | $0.11 | +83.3% |
| Q1 FY2018 | Mar 31, 2018 | -$0.17 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.13 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.28 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.06 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.26 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.44 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?